公开(公告)号：WO2018039647A1

公开(公告)日：2018-03-01

申请号：PCT/US2017/048757

申请日：2017-08-25

Applicant: AMGEN INC.

Inventor： OLLMANN, Michael ,  LI, Yang ,  ZHANG, Jun ,  BISWAS, Kaustav ,  HOMANN, Oliver ,  MIRANDA, Leslie P. ,  MURRAY, Justin K. ,  WU, Bin ,  YOON, Oh Kyu ,  ALLEN, John Gordon ,  NETIROJJANAKUL, Chawita ,  CHENG, Yuan

IPC: C12N15/113

Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.

Abstract translation: 本发明涉及用于减少ASGR1基因表达的RNAi构建体。 还描述了使用这种RNAi构建体来治疗或预防心血管疾病（例如冠状动脉疾病和心肌梗塞）并降低血清非HDL胆固醇水平的方法。

公开(公告)号：WO2014165277A2

公开(公告)日：2014-10-09

申请号：PCT/US2014/025062

申请日：2014-03-12

Applicant: AMGEN INC.

Inventor： MURRAY, Justin K. ,  HOLDER, Jerry Ryan ,  WANSKA, Malgorzata ,  TEGLEY, Christopher M. ,  FALSEY, James R. ,  DOHERTY, Elizabeth M. ,  MIRANDA, Leslie P. ,  BISWAS, Kaustav ,  WU, Bin ,  SHAM, Kelvin ,  LONG, Jason C.

IPC: C07K14/435

CPC classification number: C07K14/43518 ,  A61K38/00 ,  A61K38/1767 ,  A61K47/48284 ,  A61K47/48438 ,  A61K47/643 ,  A61K47/6817

Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

Abstract translation: 公开了包含分离的多肽的物质组合物，其是外周限制的Nav1.7抑制剂。 在一些公开的实施方案中，分离的多肽是Nav1.7的抑制剂。 其它实施方案是本发明组合物和包含本发明组合物的药物组合物的共轭实施方案。 公开了编码本发明多肽和表达载体的一些实施方案的分离的核酸，以及含有它们的重组宿主细胞。 还公开了治疗或预防疼痛的方法。

公开(公告)号：WO2010108154A2

公开(公告)日：2010-09-23

申请号：PCT/US2010/028061

申请日：2010-03-19

Applicant: AMGEN INC. ,  SULLIVAN, John K. ,  MIRANDA, Leslie P. ,  GEGG, Colin V. ,  HU, Shaw-Fen Sylvia ,  BELOUSKI, Edward J. ,  MURRAY, Justin K. ,  NGUYEN, Hung ,  WALKER, Kenneth W. ,  ARORA, Taruna ,  JACOBSEN, Frederick W. ,  LI, Yue-Sheng ,  BOONE, Thomas C.

Inventor： SULLIVAN, John K. ,  MIRANDA, Leslie P. ,  GEGG, Colin V. ,  HU, Shaw-Fen Sylvia ,  BELOUSKI, Edward J. ,  MURRAY, Justin K. ,  NGUYEN, Hung ,  WALKER, Kenneth W. ,  ARORA, Taruna ,  JACOBSEN, Frederick W. ,  LI, Yue-Sheng ,  BOONE, Thomas C.

IPC: A61K38/16

CPC classification number: C07K16/44 ,  A61K39/39591 ,  A61K47/6817 ,  A61K47/6843 ,  C07K14/43504 ,  C07K14/575 ,  C07K14/605 ,  C07K14/66 ,  C07K16/00 ,  C07K16/18 ,  C07K16/248 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/55

Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.

Abstract translation: 公开了具有SEQ ID NO：4的氨基酸序列或其药学上可接受的盐的物质组合物，包括包含与ShK，HmK和AETX-K相关的毒素肽类似物的实施方案，以及含有它们的药物组合物或药物以及 药学上可接受的载体。 一些实施方案包括半衰期延长部分。 还公开了预防或减轻多发性硬化症状的复发的方法以及使用该组合物治疗自身免疫病症的方法。